Medical Advertising Hall of Fame seeks nominations

Share this article:

The Medical Advertising Hall of Fame (MAHF) is seeking nominations for its 2008 class as it looks to a newer generation of industry contributors as potential honorees.

“The award is an enshrinement,” MAHF chairperson Scott Cotherman told MM&M, “It recognizes the life-long contributions of people who have made a significant impact on our industry in a variety of different areas, those who have also provided great service to the industry outside of their specific responsibilites.”

Cotherman, who is also CEO of Corbett Accel, said, “As you look at MAHF what you have very often is the most well-known, the names on the door, the best of the best. But that's not going to be the obvious group of people going forward with this new generation. It really gives us an opportunity to showcase people who have made great contributions, those who may not be the names on the door, if you will.” 

The deadline for MAHF nominations is Aug. 31.

MAHF seeks candidates based on two primary criteria:

• The candidate's achievement as evidenced by impact on brand and corporate success, leadership of his or her company, accomplishments in the creative, marketing/research or publishing disciplines and innovations in the advertisng process or structure.

• The contributions the candidate has made to enhance the reputation of the medical advertising industry through voluntary efforts outside his or her company. The nominee's record of advertising and service must have been accomplished in the advertising industry in the United States or with an American company abroad. The candidate must have completed his or her primary career. The council of judges shall consider the election of either living or deceased persons.

For full details on documentation and other submission requirements, contact David Gideon at 561-237-6121, email him at david@mahf.com, or visit www.mahf.com.

 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...